Praxis Precision Medicines, Inc. — FY2022 Form 10-K
Reporting period: Year ended December 31, 2022. Filed February 7, 2023. Praxis is a clinical-stage biopharmaceutical company developing central nervous system therapies through its Cerebrum small-molecule and Solidus antisense oligonucleotide platforms. It has no approved products and has not generated product-sales revenue.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | No collaboration revenue recognized; no product-sales revenue | No product-sales revenue |
| Research and development expense | $155.0 million | $120.3 million |
| General and administrative expense | $59.9 million | $47.1 million |
| Total operating expenses / operating loss | $215.0 million | $167.3 million |
| Net loss | $214.0 million | $167.1 million |
| Net loss per share, basic and diluted | $4.64 | $3.94 |
| Net cash used in operating activities | $185.0 million | $124.6 million |
As of December 31, 2022, cash and cash equivalents were $61.6 million and marketable securities were $38.9 million, totaling $100.5 million. Total assets were $115.1 million, total liabilities $39.0 million, and stockholders’ equity $76.1 million. The filing reports no borrowings or debt. Operating lease liabilities totaled $3.5 million; remaining lease payments were approximately $4.0 million.
There is no meaningful product gross margin because Praxis has no commercial product sales. The company reported $5.0 million in upfront consideration under its UCB collaboration, recorded as deferred revenue at year-end; no related revenue was recognized in 2022 because services had not yet been performed. The filing reports no income tax provision.
Changes versus FY2021
- Net loss widened by $47.0 million, while operating expenses increased by $47.7 million. R&D expense rose $34.8 million, primarily with increased clinical, manufacturing, and preclinical spending across Cerebrum and Solidus programs; G&A expense increased $12.9 million, principally due to personnel costs and stock-based compensation.
- Operating cash use increased by $60.5 million. Year-end cash, cash equivalents, and marketable securities declined from $275.9 million to $100.5 million.
- In June 2022, Praxis realigned operations around ulixacaltamide, PRAX-562, PRAX-222, PRAX-628, and preclinical programs, reducing its workforce. It recorded $1.0 million of restructuring costs, all paid by year-end.
- PRAX-114’s Phase 2/3 Aria study in major depressive disorder failed to achieve statistical significance on its primary or secondary endpoints. Praxis wound down those trials and refocused resources on other programs.
Pipeline outlook and key risks
- Ulixacaltamide: Phase 2b Essential1 trial for essential tremor was ongoing; topline results were expected in Q1 2023. A Phase 2 Parkinson’s disease trial was planned to start in Q1 2023, with results expected in Q4 2023.
- PRAX-562: The EMBOLD Phase 2 study in SCN2A- and SCN8A-related developmental and epileptic encephalopathies was expected to start in Q1 2023, with results expected in the second half of 2023.
- PRAX-222: The EMBRAVE open-label study in early-onset SCN2A-DEE was underway; first-cohort results were expected in mid-2023. Further dose escalation depended on review of initial safety and efficacy data.
- PRAX-628: A Phase 1 healthy-volunteer study began in Q4 2022; results were expected in mid-2023, followed by a planned Phase 2 focal-epilepsy study in Q4 2023.
- Funding and going concern: Management estimated that year-end liquidity, together with $11.2 million of net ATM proceeds raised after year-end, could fund operations into Q1 2024. However, the company and its auditor disclosed substantial doubt about its ability to continue as a going concern because available resources were not expected to cover at least 12 months from the financial-statement issuance date. Additional financing is required, with no assurance it will be available on acceptable terms.
- Clinical development is uncertain: candidates may fail or cause unacceptable side effects; enrollment, regulatory review, and manufacturing could be delayed. The company relies on external CROs and manufacturers, faces competition, and may need to raise dilutive capital or grant rights to partners. Future coverage, reimbursement, and pricing are uncertain.
- Other notable items: Praxis entered a UCB KCNT1 research collaboration in December 2022, with potential option and milestone payments totaling up to $98.5 million plus royalties if a resulting product is commercialized. It depends on third-party manufacturing and holds no material pending legal proceedings. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued an unqualified opinion and highlighted estimates for Essential1 accrued and prepaid R&D costs as a critical audit matter.
Important facts for investors to verify
- Whether subsequent financing extended the runway and addressed the disclosed going-concern uncertainty; confirm the current cash balance, burn rate, and dilution.
- Final results and regulatory or development consequences from the ulixacaltamide, PRAX-562, PRAX-222, and PRAX-628 studies; compare reported topline data with final analyses.
- Whether the UCB collaboration’s research obligations are being performed and whether any option, milestone, or royalty conditions have been met.
- Current program priorities, costs, and any further restructuring or discontinuation decisions, particularly following the PRAX-114 trial failure.
- Potential changes in third-party manufacturing, trial timelines, safety findings, and financing or licensing obligations that could alter the company’s operating plan.